Caplin Point announces board appointments, reports strong H1 FY26 financials

Caplin Point Laboratories Limited announced significant board appointments and leadership changes on November 5, 2025. Ashok Partheeban and Vivek Partheeban were appointed as additional directors and vice-chairmen, effective November 5, 2025, with their terms subject to shareholder approval. Concurrently, Vivek Partheeban relinquished his position as chief operating officer. Dr. K.C. John was also appointed as an additional director (non-executive independent) for a five-year term, effective the same date.

These appointments coincide with the approval of the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company reported H1 FY26 total revenue of ₹1098 Crores, an 11.9% year-over-year increase, surpassing its full-year FY21 revenue. Profit after tax (PAT) for H1 FY26 stood at ₹311 Crores, up 21.6% year-over-year.

Operational highlights include H1 FY26 US market revenue of ₹221 Crores, a 27% year-over-year growth, and cash reserves of ₹1,334 Crores with total liquid assets of ₹2,358 Crores. The board also approved an enhanced capex budget of approximately ₹1000 Crores for investment projects, aiming to augment production capacities and achieve backward integration.